Recently, the Hydralazine Hydrochloride Injection independently developed by Kindos Pharmaceutical Co., LTD., a subsidiary of King-Friend Co., LTD., has been approved by the US Food and Drug Administration (FDA) for market sale.

Hydralazine Hydrochloride Injection is suitable for patients with severe essential hypertension who cannot receive oral administration or need urgent blood pressure reduction. Data shows that the market size of Hydralazine Hydrochloride Injection in the United States exceeded 47 million US dollars in 2024.

This approval makes Kindos the first Chinese pharmaceutical company to have this variety approved for marketing in the United States. The KINDOS team, with its professional and efficient R&D and industrialization capabilities, successfully solved multiple high-difficulty technical challenges of Hydrazidine Hydrochloride Injection and achieved the milestone goal ahead of schedule. This once again proves the company's high-quality R&D efficiency and precise project management capabilities.

Since the beginning of this year, Kindos has been making continuous efforts. With the systematic advantage of efficient integration of resources throughout the entire industrial chain, it has successively achieved the approval and marketing of five new varieties in the United States, constantly strengthening and expanding the basic position of high-quality Chinese injectables in the international market.